The unprecedented changes have led to diminished vaccine usage, and created a drag that will likely dent revenues.

Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a ‌chilling effect ​on vaccine makers as ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Pfizer has signed a deal worth up to $530m with US-based vaccine technology company Novavax. This agreement will see Pfizer ...

Novavax said on Tuesday it signed a licensing ​agreement allowing Pfizer access to its technology that boosts immune ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Recent health sector developments highlight Moderna and Merck's promising skin cancer vaccine trial alongside China's declining birthrate, and significant business moves from pharmaceuticals giants ...

Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of ...

Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...